| 1 |
Lee M, Abu Rous F, Borczuk A, Liu S, Gadgeel S, Halmos B. Targeting Oncogenic Driver Mutations in Lung Cancer. 2023. [DOI: 10.1017/9781009336123] [Reference Citation Analysis]
|
| 2 |
Ye J, Wu J, Liu B. Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochim Biophys Acta Rev Cancer 2023;1878:188866. [PMID: 36842765 DOI: 10.1016/j.bbcan.2023.188866] [Reference Citation Analysis]
|
| 3 |
Hou X, Chen H, Liu Y, Gong S, Zhudai M, Shen L. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. Cancer Imaging 2023;23:20. [PMID: 36823653 DOI: 10.1186/s40644-023-00537-y] [Reference Citation Analysis]
|
| 4 |
Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer 2023. [PMID: 36797503 DOI: 10.1038/s43018-023-00515-0] [Reference Citation Analysis]
|
| 5 |
Wang Y, Zhang Y, Chen R, Tian X. Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer. Pharmacol Res Perspect 2023;11:e01047. [PMID: 36583451 DOI: 10.1002/prp2.1047] [Reference Citation Analysis]
|
| 6 |
Wu R, Liu S, Lv G, Deng C, Wang R, Zhang S, Zhu D, Wang L, Lei Y, Luo Z. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. Anticancer Drugs 2023;34:294-301. [PMID: 36730620 DOI: 10.1097/CAD.0000000000001408] [Reference Citation Analysis]
|
| 7 |
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. Int J Mol Sci 2023;24. [PMID: 36768562 DOI: 10.3390/ijms24032242] [Reference Citation Analysis]
|
| 8 |
Dinakaran D, Azad AK, Wilson BC. Photodynamic and photothermal therapy using PLGA nanoparticles. Poly(Lactic-Co-glycolic Acid) (PLGA) Nanoparticles for Drug Delivery 2023. [DOI: 10.1016/b978-0-323-91215-0.00010-8] [Reference Citation Analysis]
|
| 9 |
Rosen JC, Sacher A, Tsao M. Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg. Ther Adv Med Oncol 2023;15:175883592311601. [DOI: 10.1177/17588359231160141] [Reference Citation Analysis]
|
| 10 |
Qiu Y, Song L, Jiang G, Zhang Z, Liu X, Wang G. Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance. Pharmaceutical Fronts 2022. [DOI: 10.1055/s-0042-1758542] [Reference Citation Analysis]
|
| 11 |
Wu J, Lin Z. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Int J Mol Sci 2022;23. [PMID: 36499382 DOI: 10.3390/ijms232315056] [Reference Citation Analysis]
|
| 12 |
Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
|
| 13 |
Talwelkar SS, Mäyränpää MI, Schüler J, Linnavirta N, Hemmes A, Adinolfi S, Kankainen M, Sommergruber W, Levonen AL, Räsänen J, Knuuttila A, Verschuren EW, Wennerberg K. PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. Mol Oncol 2022. [PMID: 36423211 DOI: 10.1002/1878-0261.13342] [Reference Citation Analysis]
|
| 14 |
Liu Z, Li X, Gao J, Yin P, Teng Y, Yu P. The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. Biochemical Pharmacology 2022;205:115294. [DOI: 10.1016/j.bcp.2022.115294] [Reference Citation Analysis]
|
| 15 |
Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol 2022;15:143. [PMID: 36209184 DOI: 10.1186/s13045-022-01362-9] [Reference Citation Analysis]
|
| 16 |
Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, Cantini L, Berardi R. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers 2022;14:4765. [DOI: 10.3390/cancers14194765] [Reference Citation Analysis]
|
| 17 |
Jiang G, Song L, Qiu Y, Liu Y. 3D-QSAR and Docking Studies on Pyrimidine Derivatives of Second-Generation ALK Inhibitors. Pharmaceutical Fronts 2022;04:e136-e150. [DOI: 10.1055/s-0042-1750044] [Reference Citation Analysis]
|
| 18 |
Thapa S, A. Rather R, K. Singh S, Bhagat M. Targeting Oncogene Addiction for Cancer Therapy. Molecular Mechanisms in Cancer 2022. [DOI: 10.5772/intechopen.101244] [Reference Citation Analysis]
|
| 19 |
Tabbò F, De Filippis M, Jacobs F, Novello S. Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. Minerva Med 2022;113. [DOI: 10.23736/s0026-4806.21.07693-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel) 2022;14:1184. [PMID: 35267492 DOI: 10.3390/cancers14051184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 21 |
Gonzalez-martinez D, Roth L, Mumford TR, Guan J, Huang B, Tulpule A, Bivona TG, Bugaj LJ. Oncogenic protein condensates suppress growth factor perception and modulate drug tolerance.. [DOI: 10.1101/2022.02.02.478845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Hua G, Zhang X, Zhang M, Wang Q, Chen X, Yu R, Bao H, Liu J, Wu X, Shao Y, Liang B, Lu K. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. ESMO Open 2022;7:100337. [PMID: 35123209 DOI: 10.1016/j.esmoop.2021.100337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 23 |
Crucitta S, Cucchiara F, Mathijssen R, Mateo J, Jager A, Joosse A, Passaro A, Attili I, Petrini I, van Schaik R, Danesi R, Del Re M. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Hu L, Fan M, Shi S, Song X, Wang F, He H, Qi B. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-). Eur J Med Chem 2022;227:113963. [PMID: 34749202 DOI: 10.1016/j.ejmech.2021.113963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 25 |
Nimsarkar P, Gulhane P, Singh S. Understanding the Molecular Kinetics in NSCLC Through Computational Method. Systems Biomedicine Approaches in Cancer Research 2022. [DOI: 10.1007/978-981-19-1953-4_7] [Reference Citation Analysis]
|
| 26 |
Behel V, Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat 2022;5:312. [DOI: 10.4103/crst.crst_114_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Perumal NK, Vijayan N, Perumal MK, Halagowder D, Sivasithamparam ND. Small Molecule Inhibitors That Target Signal Transduction Pathways Involved in Oxidative Stress-Induced Cancer. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_36] [Reference Citation Analysis]
|
| 28 |
Perumal NK, Vijayan N, Perumal MK, Halagowder D, Sivasithamparam ND. Small Molecule Inhibitors That Target Signal Transduction Pathways Involved In Oxidative Stress-Induced Cancer. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-1247-3_36-1] [Reference Citation Analysis]
|
| 29 |
Hare L, Burke GAA, Turner SD. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers (Basel) 2021;13:6003. [PMID: 34885113 DOI: 10.3390/cancers13236003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Hirai N, Hatanaka Y, Hatanaka KC, Uno Y, Chiba SI, Umekage Y, Minami Y, Okumura S, Ohsaki Y, Sasaki T. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer. Transl Lung Cancer Res 2021;10:3737-44. [PMID: 34733624 DOI: 10.21037/tlcr-21-415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Pan Y, Deng C, Qiu Z, Cao C, Wu F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2021;11:713530. [PMID: 34660278 DOI: 10.3389/fonc.2021.713530] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 32 |
Yang X, Zhong J, Yu Z, Zhuo M, Zhang M, Chen R, Xia X, Zhao J. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. BMC Cancer 2021;21:1107. [PMID: 34654390 DOI: 10.1186/s12885-021-08824-2] [Reference Citation Analysis]
|
| 33 |
Inoue Y, Matsubara O, Ohira Y, Endo S, Jinn Y. A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib. Respir Med Case Rep 2021;33:101418. [PMID: 34401266 DOI: 10.1016/j.rmcr.2021.101418] [Reference Citation Analysis]
|
| 34 |
Creixell M, Meyer AS. Motif-based phosphoproteome clustering improves modeling and interpretation.. [DOI: 10.1101/2021.06.09.447799] [Reference Citation Analysis]
|
| 35 |
Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers (Basel) 2021;13:2394. [PMID: 34063424 DOI: 10.3390/cancers13102394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer 2021;21:309. [PMID: 33761908 DOI: 10.1186/s12885-021-08005-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Taniguchi K, Konishi H, Yoshinaga A, Tsugane M, Takahashi H, Nishisaka F, Shishido Y, Asai A. Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. Sci Rep 2021;11:6685. [PMID: 33758275 DOI: 10.1038/s41598-021-86021-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 38 |
Talwelkar SS, Mäyränpää MI, Schüler J, Linnavirta N, Hemmes A, Adinolfi S, Kankainen M, Sommergruber W, Levonen A, Räsänen J, Knuuttila A, Verschuren EW, Wennerberg K. PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer.. [DOI: 10.1101/2021.03.18.435801] [Reference Citation Analysis]
|
| 39 |
Tabbò F, Reale ML, Bironzo P, Scagliotti GV. Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Transl Lung Cancer Res 2020;9:2545-56. [PMID: 33489817 DOI: 10.21037/tlcr-20-372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 40 |
Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Thorac Cancer 2021;12:643-9. [PMID: 33470536 DOI: 10.1111/1759-7714.13825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 41 |
Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 42 |
Andraos E, Dignac J, Meggetto F. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target. Cancers (Basel) 2021;13:E144. [PMID: 33466277 DOI: 10.3390/cancers13010144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Katayama R. Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance. Therapeutic Strategies to Overcome ALK Resistance in Cancer 2021. [DOI: 10.1016/b978-0-12-821774-0.00015-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 44 |
Wang S, Shi Y, Han X. [Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:1014-22. [PMID: 33203201 DOI: 10.3779/j.issn.1009-3419.2020.101.44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 45 |
Loong HH, Wong CKH, Leung LKS, Chan CPK, Chang A, Zhou ZY, Xie J, Gibbs M. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Eff Resour Alloc 2020;18:50. [PMID: 33292314 DOI: 10.1186/s12962-020-00244-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
D'Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, Ferrari K, Voltolini L, Darlow J, Roviello G. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers (Basel) 2020;12:E3293. [PMID: 33172113 DOI: 10.3390/cancers12113293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 47 |
Shi Y, Mo X, Hong S, Li T, Chen B, Chen G. Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma. Biomed Res Int 2020;2020:4965670. [PMID: 33204699 DOI: 10.1155/2020/4965670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Codony-Servat J, García-Roman S, Molina-Vila MÁ, Bertran-Alamillo J, Viteri S, d'Hondt E, Rosell R. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. Transl Oncol 2021;14:100887. [PMID: 33129112 DOI: 10.1016/j.tranon.2020.100887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 49 |
Kadlec B. Alectinib in the treatment of advanced ALK + NSCLC. Onkologie 2020;14:135-138. [DOI: 10.36290/xon.2020.073] [Reference Citation Analysis]
|
| 50 |
Fordham AM, Xie J, Gifford AJ, Wadham C, Morgan LT, Mould EVA, Fadia M, Zhai L, Massudi H, Ali ZS, Marshall GM, Lukeis RE, Fletcher JI, MacKenzie KL, Trahair TN. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. Br J Cancer 2020;123:1101-13. [PMID: 32684628 DOI: 10.1038/s41416-020-0996-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 51 |
Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med 2020;9:E1870. [PMID: 32549358 DOI: 10.3390/jcm9061870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 52 |
Shao Y, Zhong D. [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI]. Zhongguo Fei Ai Za Zhi 2020;23:381-7. [PMID: 32429639 DOI: 10.3779/j.issn.1009-3419.2020.101.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 53 |
Munira S, Yuki R, Saito Y, Nakayama Y. ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation. Cancers (Basel) 2020;12:E1054. [PMID: 32344689 DOI: 10.3390/cancers12041054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 54 |
Oya Y, Kuroda H, Nakada T, Takahashi Y, Sakakura N, Hida T. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement. Int J Mol Sci 2020;21:E2623. [PMID: 32283823 DOI: 10.3390/ijms21072623] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 55 |
Emdadi A, Eslahchi C. DSPLMF: A Method for Cancer Drug Sensitivity Prediction Using a Novel Regularization Approach in Logistic Matrix Factorization. Front Genet 2020;11:75. [PMID: 32174963 DOI: 10.3389/fgene.2020.00075] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 56 |
Yanagitani N, Uchibori K, Koike S, Tsukahara M, Kitazono S, Yoshizawa T, Horiike A, Ohyanagi F, Tambo Y, Nishikawa S, Fujita N, Katayama R, Nishio M. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci 2020;111:932-9. [PMID: 31961053 DOI: 10.1111/cas.14314] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 57 |
Palve V, Liao Y, Remsing Rix LL, Rix U. Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Semin Cancer Biol 2021;68:209-29. [PMID: 32044472 DOI: 10.1016/j.semcancer.2020.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 58 |
Zhu C, Zhuang W, Chen L, Yang W, Ou WB. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 2020;9:111-38. [PMID: 32206559 DOI: 10.21037/tlcr.2020.01.09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 59 |
Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Target Oncol 2019;14:169-78. [PMID: 30888598 DOI: 10.1007/s11523-019-00628-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 60 |
Kumar B, Sharma D, Gorantala J, Magani SKJ. Small Molecule-Targeted Therapies for GI Cancers: Success and Failures. Novel therapeutic approaches for gastrointestinal malignancies 2020. [DOI: 10.1007/978-981-15-5471-1_4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 61 |
Shrestha N, Nimick M, Dass P, Rosengren RJ, Ashton JC. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Sci Rep 2019;9:18842. [PMID: 31827192 DOI: 10.1038/s41598-019-55376-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 62 |
Delmonte A, Burgio MA, Verlicchi A, Bronte G, Cravero P, Ulivi P, Martinelli G, Crinò L. New generation anaplastic lymphoma kinase inhibitors. Transl Lung Cancer Res 2019;8:S280-9. [PMID: 31857951 DOI: 10.21037/tlcr.2019.09.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 63 |
Pinsolle J, McLeer-Florin A, Giaj Levra M, de Fraipont F, Emprou C, Gobbini E, Toffart AC. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Front Med (Lausanne) 2019;6:233. [PMID: 31737634 DOI: 10.3389/fmed.2019.00233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 64 |
Ponnusamy S, Asemota S, Schwartzberg LS, Guestini F, McNamara KM, Pierobon M, Font-Tello A, Qiu X, Xie Y, Rao PK, Thiyagarajan T, Grimes B, Johnson DL, Fleming MD, Pritchard FE, Berry MP, Oswaks R, Fine RE, Brown M, Sasano H, Petricoin EF, Long HW, Narayanan R. Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. iScience 2019;21:341-58. [PMID: 31698248 DOI: 10.1016/j.isci.2019.10.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 65 |
Liu J, Mu Z, Liu L, Li K, Jiang R, Chen P, Zhou Q, Jin M, Ma Y, Xie Y, Xiang J, Li B, Ma Y, Mao X, Zhang L, Zhang T, Wu D. Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients. Drug Des Devel Ther 2019;13:1809-17. [PMID: 31213769 DOI: 10.2147/DDDT.S196189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 66 |
Jin J, Wu X, Yin J, Li M, Shen J, Li J, Zhao Y, Zhao Q, Wu J, Wen Q, Cho CH, Yi T, Xiao Z, Qu L. Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Front Oncol 2019;9:263. [PMID: 31058077 DOI: 10.3389/fonc.2019.00263] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 67 |
Cannataro VL, Townsend JP. Neutral Theory and the Somatic Evolution of Cancer. Mol Biol Evol 2018;35:1308-15. [PMID: 29684198 DOI: 10.1093/molbev/msy079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 68 |
Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell 2018;33:801-15. [PMID: 29763622 DOI: 10.1016/j.ccell.2018.03.025] [Cited by in Crossref: 122] [Cited by in F6Publishing: 97] [Article Influence: 30.5] [Reference Citation Analysis]
|
| 69 |
Okuda K, Haneda H, Yokota K, Tatematsu T, Nakanishi R. The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients. J Thorac Dis 2018;10:S4013-6. [PMID: 30631542 DOI: 10.21037/jtd.2018.09.43] [Reference Citation Analysis]
|
| 70 |
Büttner R, Heydt C, Merkelbach-bruse S. Genomic Applications in Pulmonary Malignancies. Genomic Applications in Pathology 2019. [DOI: 10.1007/978-3-319-96830-8_27] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 71 |
Woyach JA. Resistance to Anti-Cancer Therapeutics. Precision Cancer Medicine 2019. [DOI: 10.1007/978-3-030-23637-3_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 72 |
Schildgen V, Schildgen O. Implementing Companion Diagnostic Testing in the Clinic. Companion and Complementary Diagnostics 2019. [DOI: 10.1016/b978-0-12-813539-6.00022-5] [Reference Citation Analysis]
|
| 73 |
Duffield E. Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_6] [Reference Citation Analysis]
|
| 74 |
Villanueva NA, Giustini NP, Bazhenova LA. Anaplastic Lymphoma Kinase. Targeted Therapies for Lung Cancer 2019. [DOI: 10.1007/978-3-030-17832-1_2] [Reference Citation Analysis]
|
| 75 |
Pal P, Cabanero M, Tsao M. Pulmonary Adenocarcinoma—Pathology and Molecular Testing. Pulmonary Adenocarcinoma: Approaches to Treatment 2019. [DOI: 10.1016/b978-0-323-55433-6.00002-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhang D, Zhu S. Targeted therapies for advanced non-small cell lung cancer. Oncotarget 2018;9:37589-607. [PMID: 30680072 DOI: 10.18632/oncotarget.26428] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 77 |
Wang X, Zhong D. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:686-91. [PMID: 30201068 DOI: 10.3779/j.issn.1009-3419.2018.09.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 78 |
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 2018;24:5963-76. [PMID: 30072474 DOI: 10.1158/1078-0432.CCR-18-0876] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 79 |
Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. Oncol Lett 2018;16:4219-22. [PMID: 30214557 DOI: 10.3892/ol.2018.9158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 80 |
Li J, Huang Y, Wu M, Wu C, Li X, Bao J. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. Sci Rep 2018;8:10664. [PMID: 30006516 DOI: 10.1038/s41598-018-28752-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 81 |
Ni W, Chen W, Lu Y. Emerging findings into molecular mechanism of brain metastasis. Cancer Med 2018;7:3820-33. [PMID: 29992751 DOI: 10.1002/cam4.1667] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 82 |
An J, Xue Y, Long M, Zhang G, Zhang J, Su H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. Oncotarget 2017;8:39230-40. [PMID: 28424406 DOI: 10.18632/oncotarget.16837] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 83 |
Nakamichi S, Seike M, Miyanaga A, Chiba M, Zou F, Takahashi A, Ishikawa A, Kunugi S, Noro R, Kubota K, Gemma A. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. Oncotarget 2018;9:27242-55. [PMID: 29930762 DOI: 10.18632/oncotarget.25531] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 84 |
Berradi H, Kaanane H, El Kadmiri N, Nadifi S. Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. Gene Reports 2018;11:196-204. [DOI: 10.1016/j.genrep.2018.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 85 |
Thumallapally N, Parylo S, Vennepureddy A, Ibrahim U, Sokoloff A. Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature. World J Oncol 2018;9:50-5. [PMID: 29760833 DOI: 10.14740/wjon1090e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 86 |
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H, Cottrell CE, Pfeifer JD, Kulkarni S, Govindan R, Konnick EQ, Lockwood CM, Duncavage EJ. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol 2018;31:791-808. [PMID: 29327716 DOI: 10.1038/modpathol.2017.181] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 87 |
Hong X, Chen Q, Ding L, Liang Y, Zhou N, Fang W, Chen X, Wu H. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget 2017;8:41631-40. [PMID: 28427213 DOI: 10.18632/oncotarget.15892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 88 |
Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Med Oncol 2018;35:72. [PMID: 29666949 DOI: 10.1007/s12032-018-1133-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 89 |
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 2018;24:3334-47. [PMID: 29636358 DOI: 10.1158/1078-0432.CCR-17-2452] [Cited by in Crossref: 124] [Cited by in F6Publishing: 137] [Article Influence: 24.8] [Reference Citation Analysis]
|
| 90 |
Zhang S, Yan B, Zheng J, Zhao J, Zhou J. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget 2016;7:63758-66. [PMID: 27563816 DOI: 10.18632/oncotarget.11494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 91 |
Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers (Basel). 2018;10:E107. [PMID: 29617304 DOI: 10.3390/cancers10040107] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 92 |
Ziogas DC, Tsiara A, Tsironis G, Lykka M, Liontos M, Bamias A, Dimopoulos MA. Treating ALK-positive non-small cell lung cancer. Ann Transl Med 2018;6:141. [PMID: 29862230 DOI: 10.21037/atm.2017.11.34] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 93 |
Dalal AA, Guerin A, Mutebi A, Culver KW. Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis. J Drug Assess 2018;7:21-7. [PMID: 29707414 DOI: 10.1080/21556660.2018.1445092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 94 |
Yokoyama A, Tamura A, Miyakawa K, Kusaka K, Shimada M, Hirose T, Matsui H, Kitani M, Hebisawa A, Ohta K. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. Intern Med 2018;57:2377-82. [PMID: 29526950 DOI: 10.2169/internalmedicine.0383-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 95 |
Hu W, Liu Y, Chen J. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Oncotarget 2017;8:25046-54. [PMID: 28212572 DOI: 10.18632/oncotarget.15337] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 96 |
Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med 2018;24:512-7. [PMID: 29505033 DOI: 10.1038/nm.4497] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 23.6] [Reference Citation Analysis]
|
| 97 |
Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers (Basel) 2018;10:E62. [PMID: 29495603 DOI: 10.3390/cancers10030062] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 98 |
Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget 2016;7:65185-95. [PMID: 27533086 DOI: 10.18632/oncotarget.11218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 99 |
Xing P, Wang S, Hao X, Zhang T, Li J. Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases. Oncotarget 2016;7:84666-74. [PMID: 27835868 DOI: 10.18632/oncotarget.13179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 100 |
Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018;17:52. [PMID: 29455675 DOI: 10.1186/s12943-018-0810-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 95] [Article Influence: 16.6] [Reference Citation Analysis]
|
| 101 |
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 2018;17:58. [PMID: 29455648 DOI: 10.1186/s12943-018-0782-4] [Cited by in Crossref: 377] [Cited by in F6Publishing: 386] [Article Influence: 75.4] [Reference Citation Analysis]
|
| 102 |
Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci 2018;109:572-80. [PMID: 29336091 DOI: 10.1111/cas.13504] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 103 |
Amin AD, Li L, Rajan SS, Gokhale V, Groysman MJ, Pongtornpipat P, Tapia EO, Wang M, Schatz JH. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget 2016;7:23715-29. [PMID: 27009859 DOI: 10.18632/oncotarget.8173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 104 |
Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer 2016;2:350-64. [PMID: 27819059 DOI: 10.1016/j.trecan.2016.05.010] [Cited by in Crossref: 114] [Cited by in F6Publishing: 124] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 105 |
Li L, Wang Y, Peng T, Zhang K, Lin C, Han R, Lu C, He Y. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget 2016;7:34442-52. [PMID: 27144340 DOI: 10.18632/oncotarget.9120] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 106 |
Mascaux C, Tsao M, Hirsch FR. Molecular Testing in Lung Cancer. IASLC Thoracic Oncology 2018. [DOI: 10.1016/b978-0-323-52357-8.00018-4] [Reference Citation Analysis]
|
| 107 |
Gray AL, Coleman DT, Shi R, Cardelli JA. Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity. Oncotarget 2016;7:32695-706. [PMID: 27127175 DOI: 10.18632/oncotarget.9016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 108 |
Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, Wu J, Ren X, Zhang J. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016;7:12289-304. [PMID: 26802023 DOI: 10.18632/oncotarget.6935] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 109 |
Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno M, Altruda F, Monti S, Chiarle R. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget 2016;7:33316-30. [PMID: 27119231 DOI: 10.18632/oncotarget.8955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 110 |
Pan P, Yu H, Liu Q, Kong X, Chen H, Chen J, Liu Q, Li D, Kang Y, Sun H, Zhou W, Tian S, Cui S, Zhu F, Li Y, Huang Y, Hou T. Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. ACS Cent Sci 2017;3:1208-20. [PMID: 29202023 DOI: 10.1021/acscentsci.7b00419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 111 |
Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:iii42-50. [PMID: 27573756 DOI: 10.1093/annonc/mdw305] [Cited by in Crossref: 72] [Cited by in F6Publishing: 86] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 112 |
Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, Leggett AL, Li T, Wang Y, Zhang T, Kim TJ, Hong SH, Poudel-Neupane N, Silkes M, Mudianto T, Tan L, Shimamura T, Meyerson M, Bass AJ, Watanabe H, Gray NS, Young RA, Wong KK, Hammerman PS. Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov 2018;8:59-73. [PMID: 29054992 DOI: 10.1158/2159-8290.CD-17-0461] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 113 |
Wilson JL, Kefaloyianni E, Stopfer L, Harrison C, Sabbisetti VS, Fraenkel E, Lauffenburger DA, Herrlich A. Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding. Mol Cancer Res 2018;16:147-61. [PMID: 29018056 DOI: 10.1158/1541-7786.MCR-17-0140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 114 |
Cao S, Nambudiri VE. Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers (Basel) 2017;9:E123. [PMID: 28895885 DOI: 10.3390/cancers9090123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 115 |
El Baroudi M, Machiels JP, Schmitz S. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck. Cancer Biol Ther 2017;18:775-82. [PMID: 28886272 DOI: 10.1080/15384047.2017.1373212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 116 |
Velcheti V, Pennell NA. Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. Ann Transl Med 2017;5:378. [PMID: 29057238 DOI: 10.21037/atm.2017.08.24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 117 |
Kobayashi T, Fujimoto H, D'Alessandro-Gabazza C, Gabazza EC, Hataji O. Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. J Thorac Dis 2017;9:2847-51. [PMID: 29221254 DOI: 10.21037/jtd.2017.08.114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 118 |
Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14:735-748. [PMID: 28857077 DOI: 10.1038/nrclinonc.2017.127] [Cited by in Crossref: 171] [Cited by in F6Publishing: 179] [Article Influence: 28.5] [Reference Citation Analysis]
|
| 119 |
Li Y, Su S, Cai G, Lin Q, Zhou Y, Ouyang J, Chen B, Ye J, Wu X, Chen C. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. Mol Clin Oncol 2017;7:173-82. [PMID: 28781781 DOI: 10.3892/mco.2017.1306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 120 |
Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. Mol Cancer Ther 2017;16:1623-33. [PMID: 28500237 DOI: 10.1158/1535-7163.MCT-17-0008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 121 |
Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch 2017;471:221-33. [PMID: 28730537 DOI: 10.1007/s00428-017-2183-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 122 |
Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther 2017;11:2047-63. [PMID: 28740365 DOI: 10.2147/DDDT.S113500] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 123 |
Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients. Adv Ther 2017;34:1673-85. [PMID: 28578501 DOI: 10.1007/s12325-017-0551-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 124 |
Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017;77:813-27. [PMID: 28378229 DOI: 10.1007/s40265-017-0732-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 125 |
Arbour KC, Riely GJ. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017;31:101-11. [PMID: 27912826 DOI: 10.1016/j.hoc.2016.08.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 126 |
Choi SH, Kim DH, Choi YJ, Kim SY, Lee JE, Sung KJ, Kim WS, Choi CM, Rho JK, Lee JC. Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement. Oncotarget 2017;8:58771-80. [PMID: 28938595 DOI: 10.18632/oncotarget.17680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 127 |
Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS. Discovery of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem 2017;136:497-510. [PMID: 28528303 DOI: 10.1016/j.ejmech.2017.04.079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 128 |
Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. Adv Ther 2017;34:1145-56. [PMID: 28405961 DOI: 10.1007/s12325-017-0527-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 129 |
Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci Rep 2017;7:1232. [PMID: 28450729 DOI: 10.1038/s41598-017-00791-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 130 |
Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget 2017;8:59889-900. [PMID: 28938691 DOI: 10.18632/oncotarget.17431] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 131 |
Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 2017;77:3551-63. [PMID: 28428274 DOI: 10.1158/0008-5472.CAN-17-0109] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 132 |
Liao J, Lin J, Lin D, Zou C, Kurata J, Lin R, He Z, Su Y. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. Sci Rep 2017;7:781. [PMID: 28396596 DOI: 10.1038/s41598-017-00901-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 133 |
Mileham KF, Ersek JL, Kim ES, Wistuba II. Lung Adenocarcinoma. Textbook of Uncommon Cancer 2017. [DOI: 10.1002/9781119196235.ch19] [Reference Citation Analysis]
|
| 134 |
Lu YQ, Lu KH. Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer. Chronic Dis Transl Med 2017;3:1-7. [PMID: 29063051 DOI: 10.1016/j.cdtm.2017.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 135 |
Rashdan S, Gerber DE. A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Transl Cancer Res 2017;6:S78-82. [PMID: 28680831 DOI: 10.21037/tcr.2017.02.12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 136 |
Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov 2017;7:137-55. [PMID: 28122866 DOI: 10.1158/2159-8290.CD-16-1123] [Cited by in Crossref: 282] [Cited by in F6Publishing: 306] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 137 |
Drizou M, Kotteas EA, Syrigos N. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. Clin Transl Oncol 2017;19:658-66. [PMID: 28054318 DOI: 10.1007/s12094-016-1605-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 138 |
Seike M. Mechanism of Resistance to Targeted Molecular Therapy. Molecular Targeted Therapy of Lung Cancer 2017. [DOI: 10.1007/978-981-10-2002-5_13] [Reference Citation Analysis]
|
| 139 |
Shiau C, Tsao M. Molecular Testing in Lung Cancer. Diagnostic Molecular Pathology 2017. [DOI: 10.1016/b978-0-12-800886-7.00023-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 140 |
Hatcher JM, Gray NS. Small Molecule Inhibitors of ALK. Topics in Medicinal Chemistry 2017. [DOI: 10.1007/7355_2017_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 141 |
Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Sci 2017;108:53-60. [PMID: 27783866 DOI: 10.1111/cas.13111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 142 |
Dong X, Fernandez-Salas E, Li E, Wang S. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia 2016;18:162-71. [PMID: 26992917 DOI: 10.1016/j.neo.2016.02.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 143 |
Tran PN, Klempner SJ. Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. Front Med (Lausanne) 2016;3:65. [PMID: 27965961 DOI: 10.3389/fmed.2016.00065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 144 |
Zhao Z, Verma V, Zhang M. Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biol Ther. 2015;16:1691-1701. [PMID: 26529396 DOI: 10.1080/15384047.2015.1095407] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 145 |
Xue Y, Hou S, Ji H, Han X. Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. Protein Cell 2017;8:178-90. [PMID: 27757846 DOI: 10.1007/s13238-016-0330-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 146 |
Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther 2016;9:6361-76. [PMID: 27799783 DOI: 10.2147/OTT.S98347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 147 |
Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol 2017;22:18-51. [PMID: 27743148 DOI: 10.1007/s10147-016-1045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 148 |
Kobayashi T, Fujimoto H, Gabazza EC. Efficacy of crizotinib in ALK fusion variants. J Thorac Dis 2016;8:E1381-3. [PMID: 27867635 DOI: 10.21037/jtd.2016.10.62] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 149 |
Sullivan I, Planchard D. Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial". J Thorac Dis 2016;8:E1287-92. [PMID: 27867609 DOI: 10.21037/jtd.2016.10.57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 150 |
Buetti-Dinh A, O'Hare T, Friedman R. Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS One 2016;11:e0163011. [PMID: 27669408 DOI: 10.1371/journal.pone.0163011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 151 |
Oh SJ, Noh KH, Lee YH, Hong SO, Song KH, Lee HJ, Kim S, Kim TM, Jeon JH, Seo JH, Kim DW, Kim TW. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. Oncotarget 2015;6:40255-67. [PMID: 26517679 DOI: 10.18632/oncotarget.5434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 152 |
Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.. [DOI: 10.1101/075846] [Reference Citation Analysis]
|
| 153 |
Le T, Gerber DE. ALK alterations and inhibition in lung cancer. Semin Cancer Biol 2017;42:81-8. [PMID: 27637426 DOI: 10.1016/j.semcancer.2016.08.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 154 |
Li J, Liu W, Luo H, Bao J. Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs. J Mol Model 2016;22:231. [PMID: 27585676 DOI: 10.1007/s00894-016-3099-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 155 |
Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget 2015;6:30149-64. [PMID: 26338968 DOI: 10.18632/oncotarget.4999] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 156 |
Terra SB, Jang JS, Bi L, Kipp BR, Jen J, Yi ES, Boland JM. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol 2016;29:824-31. [PMID: 27174587 DOI: 10.1038/modpathol.2016.89] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 157 |
Ulivi P. Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand? Int J Mol Sci 2016;17:E1186. [PMID: 27455248 DOI: 10.3390/ijms17071186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 158 |
Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Endocrine 2016;53:145-56. [PMID: 26370117 DOI: 10.1007/s12020-015-0739-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 159 |
Yu Y, Ding Z, Zhu L, Teng H, Lu S. Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. Springerplus 2016;5:894. [PMID: 27386342 DOI: 10.1186/s40064-016-2607-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 160 |
Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Manag 2016;5:79-90. [PMID: 30643552 DOI: 10.2217/lmt-2016-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 161 |
Castellanos EH, Horn L. Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist 2016;21:755-61. [PMID: 27053502 DOI: 10.1634/theoncologist.2015-0396] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 162 |
Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn 2016;16:737-49. [PMID: 27139190 DOI: 10.1080/14737159.2016.1181545] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 163 |
Shiroyama T, Tamiya M, Hayama M, Nishihara T, Nishida T, Tanaka A, Morishita N, Suzuki H, Okamoto N, Kawahara K, Hirashima T. A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report. J Thorac Dis 2016;8:E345-8. [PMID: 27162697 DOI: 10.21037/jtd.2016.03.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 164 |
Rothschild SI. New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Ther Clin Risk Manag 2016;12:735-41. [PMID: 27217763 DOI: 10.2147/TCRM.S87876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW. Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. J Pathol Transl Med 2016;50:197-203. [PMID: 27086595 DOI: 10.4132/jptm.2016.03.09] [Cited by in Crossref: 49] [Cited by in F6Publishing: 64] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 166 |
Saber A, van der Wekken AJ, Kok K, Terpstra MM, Bosman LJ, Mastik MF, Timens W, Schuuring E, Hiltermann TJ, Groen HJ, van den Berg A. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS One 2016;11:e0153065. [PMID: 27045755 DOI: 10.1371/journal.pone.0153065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 167 |
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-77. [PMID: 25738220 DOI: 10.1097/JTO.0000000000000516] [Cited by in Crossref: 239] [Cited by in F6Publishing: 266] [Article Influence: 34.1] [Reference Citation Analysis]
|
| 168 |
Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget 2015;6:5720-34. [PMID: 25749034 DOI: 10.18632/oncotarget.3122] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 169 |
Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus 2016;8:e513. [PMID: 27026837 DOI: 10.7759/cureus.513] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 170 |
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35. [PMID: 25979929 DOI: 10.1158/1078-0432.CCR-14-2791] [Cited by in Crossref: 168] [Cited by in F6Publishing: 193] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 171 |
Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book 2015;:e165-73. [PMID: 25993168 DOI: 10.14694/EdBook_AM.2015.35.e165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 172 |
Romanidou O, Landi L, Cappuzzo F, Califano R. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol 2016;8:176-87. [PMID: 27239236 DOI: 10.1177/1758834016631531] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 173 |
Mano H. The EML4-ALK oncogene: targeting an essential growth driver in human cancer. Proc Jpn Acad Ser B Phys Biol Sci 2015;91:193-201. [PMID: 25971657 DOI: 10.2183/pjab.91.193] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 174 |
Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci 2016;12:273-82. [PMID: 26929734 DOI: 10.7150/ijbs.14951] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 175 |
Plönes T, Engel-Riedel W, Stoelben E, Limmroth C, Schildgen O, Schildgen V. Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. J Pers Med 2016;6:E3. [PMID: 26784235 DOI: 10.3390/jpm6010003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 176 |
Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016;8:32-47. [PMID: 26753004 DOI: 10.1177/1758834015617355] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 177 |
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci 2016;73:1209-24. [PMID: 26755435 DOI: 10.1007/s00018-015-2117-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 178 |
Mirone G, Perna S, Marfe G. Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance to Targeted Anti-Cancer Therapeutics 2016. [DOI: 10.1007/978-3-319-46091-8_2] [Reference Citation Analysis]
|
| 179 |
Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol 2016;11:287-99. [PMID: 26723239 DOI: 10.1016/j.jtho.2015.10.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 180 |
Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine 2016;3:54-66. [PMID: 26870817 DOI: 10.1016/j.ebiom.2015.12.009] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 181 |
Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei) 2015;5:19. [PMID: 26613930 DOI: 10.7603/s40681-015-0019-4] [Cited by in Crossref: 203] [Cited by in F6Publishing: 218] [Article Influence: 25.4] [Reference Citation Analysis]
|
| 182 |
Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, Jänne PA, Gray NS. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem 2015;58:9296-308. [PMID: 26568289 DOI: 10.1021/acs.jmedchem.5b01136] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 183 |
Fan T, Song YJ, Liu XL. Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review. Mol Clin Oncol 2016;4:203-5. [PMID: 26893862 DOI: 10.3892/mco.2015.684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 184 |
Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib. Clin Chem 2016;62:252-61. [PMID: 26585927 DOI: 10.1373/clinchem.2015.245860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 185 |
West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book 2013. [PMID: 23714521 DOI: 10.1200/EdBook_AM.2013.33.e272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Mologni L. Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World J Clin Oncol 2015; 6(5): 104-108 [PMID: 26468446 DOI: 10.5306/wjco.v6.i5.104] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 187 |
Guo L, Zhang H, Shao W, Chen B. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Des Devel Ther 2015;9:5491-7. [PMID: 26491259 DOI: 10.2147/DDDT.S91988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 188 |
Devarakonda S, Ganesh B, Mann J, Govindan R. Crizotinib: an orphan drug for treating non-small-cell lung cancer. Expert Opinion on Orphan Drugs 2015;3:1209-18. [DOI: 10.1517/21678707.2015.1086334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 189 |
Gandhi S, Chen H, Zhao Y, Dy GK. First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl) 2015;6:71-82. [PMID: 28210152 DOI: 10.2147/LCTT.S63491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 190 |
Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Endocrine 2016;53:145-56. [PMID: 26370117 DOI: 10.1007/s12020-015-0739-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 191 |
Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015;7:274-90. [PMID: 26327925 DOI: 10.1177/1758834015590593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 192 |
Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 2015;5:390-401. [PMID: 26579470 DOI: 10.1016/j.apsb.2015.07.001] [Cited by in Crossref: 257] [Cited by in F6Publishing: 285] [Article Influence: 32.1] [Reference Citation Analysis]
|
| 193 |
Fu S, Wang HY, Wang F, Huang MY, Deng L, Zhang X, Ye ZL, Shao JY. Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chin J Cancer 2015;34:404-12. [PMID: 26253541 DOI: 10.1186/s40880-015-0032-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 194 |
Jokinen E, Laurila N, Koivunen P, Koivunen JP. Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. Oncotarget 2014;5:9295-307. [PMID: 25238228 DOI: 10.18632/oncotarget.2424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 195 |
Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM, Baek IJ, Rho JK, Lee JC. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. BMC Cancer 2015;15:553. [PMID: 26219569 DOI: 10.1186/s12885-015-1543-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 196 |
Kumar M, Ernani V, Owonikoko TK. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med 2015;45:55-66. [PMID: 26187108 DOI: 10.1016/j.mam.2015.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 197 |
Muller E, Brault B, Holmes A, Legros A, Jeannot E, Campitelli M, Rousselin A, Goardon N, Frébourg T, Krieger S, Crouet H, Nicolas A, Sastre X, Vaur D, Castéra L. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Med 2015;4:1484-93. [PMID: 26155992 DOI: 10.1002/cam4.492] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 198 |
Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015;28:70-81. [PMID: 26144315 DOI: 10.1016/j.ccell.2015.05.010] [Cited by in Crossref: 292] [Cited by in F6Publishing: 261] [Article Influence: 36.5] [Reference Citation Analysis]
|
| 199 |
Jamal-hanjani M, Lee S. Lung cancer. Lung Cancer Management 2015;4:117-123. [DOI: 10.2217/lmt.15.11] [Reference Citation Analysis]
|
| 200 |
Wu D, Jin G, Zhao D, Zhang Y, Zhao J, Yu H. [Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro]. Zhongguo Fei Ai Za Zhi 2015;18:330-9. [PMID: 26104888 DOI: 10.3779/j.issn.1009-3419.2015.06.02] [Reference Citation Analysis]
|
| 201 |
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, Meyerson M, Root DE, Jänne PA, Garraway LA. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 2015;27:397-408. [PMID: 25759024 DOI: 10.1016/j.ccell.2015.02.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 133] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 202 |
Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget 2014;5:4920-8. [PMID: 24952482 DOI: 10.18632/oncotarget.2055] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 203 |
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest 2015;125:1780-9. [PMID: 25932675 DOI: 10.1172/JCI76094] [Cited by in Crossref: 307] [Cited by in F6Publishing: 314] [Article Influence: 38.4] [Reference Citation Analysis]
|
| 204 |
Isozaki H, Takigawa N, Kiura K. Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) 2015;7:763-83. [PMID: 25941796 DOI: 10.3390/cancers7020763] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 205 |
Kanaan Z, Kloecker GH, Paintal A, Perez CA. Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther 2015;8:885-92. [PMID: 25945060 DOI: 10.2147/OTT.S67262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 206 |
Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, Pillon M, Moro S, Basso G, Rosolen A, Bonvini P. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors. PLoS One 2015;10:e0121378. [PMID: 25874976 DOI: 10.1371/journal.pone.0121378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 207 |
Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget 2018;9:24914-26. [PMID: 29861842 DOI: 10.18632/oncotarget.3674] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 208 |
López-ríos F, de Castro J, Concha Á, Garrido P, Gómez-román J, Isla D, Ramírez J, Paz-ares L, Sanz J, Felip E. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Revista Española de Patología 2015;48:80-89. [DOI: 10.1016/j.patol.2014.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 209 |
Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixidó J, Costa C, Borrell JI. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res 2013;2:72-86. [PMID: 25806218 DOI: 10.3978/j.issn.2218-6751.2013.03.1] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
|
| 210 |
Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014;3:250-61. [PMID: 25806308 DOI: 10.3978/j.issn.2218-6751.2014.03.01] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
|
| 211 |
Morán T, Quiroga V, Gil Mde L, Vilà L, Pardo N, Carcereny E, Capdevila L, Muñoz-Mármol AM, Rosell R. Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013;2:128-41. [PMID: 25806224 DOI: 10.3978/j.issn.2218-6751.2013.03.04] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 212 |
Mologni L. Expanding the portfolio of anti-ALK weapons. Transl Lung Cancer Res 2015;4:5-7. [PMID: 25806340 DOI: 10.3978/j.issn.2218-6751.2014.07.02] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 213 |
Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015;6:6377. [PMID: 25758528 DOI: 10.1038/ncomms7377] [Cited by in Crossref: 376] [Cited by in F6Publishing: 405] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 214 |
Zhou J, Zheng J, Zhao J, Sheng Y, Ding W, Zhou J. Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. Thorac Cancer 2015;6:216-9. [PMID: 26273361 DOI: 10.1111/1759-7714.12146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 215 |
Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D. Novel ALK inhibitors in clinical use and development. J Hematol Oncol 2015;8:17. [PMID: 25888090 DOI: 10.1186/s13045-015-0122-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 216 |
Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 2015;4:953-965. [PMID: 25727400 DOI: 10.1002/cam4.413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 217 |
Proia DA, Bates RC. HSP90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact. Heat Shock Proteins 2015. [DOI: 10.1007/978-3-319-17211-8_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 218 |
Palmer RH, Hallberg B. The ALK Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies 2015. [DOI: 10.1007/978-3-319-11888-8_1] [Reference Citation Analysis]
|
| 219 |
Büttner R, Odenthal M, Merkelbach-bruse S. Genomic Applications in Pulmonary Malignancies. Genomic Applications in Pathology 2015. [DOI: 10.1007/978-1-4939-0727-4_24] [Reference Citation Analysis]
|
| 220 |
Mano H. Chromosomal Translocations in Lung Cancer. Chromosomal Translocations and Genome Rearrangements in Cancer 2015. [DOI: 10.1007/978-3-319-19983-2_18] [Reference Citation Analysis]
|
| 221 |
Blackhall FH. Strategies in ALK Rearranged NSCLC Patients. New Therapeutic Strategies in Lung Cancers 2015. [DOI: 10.1007/978-3-319-06062-0_10] [Reference Citation Analysis]
|
| 222 |
Ma L, Zhang S. [Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:850-4. [PMID: 25539610 DOI: 10.3779/j.issn.1009-3419.2014.12.05] [Reference Citation Analysis]
|
| 223 |
Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32. [PMID: 25429239 DOI: 10.2147/CLEP.S69718] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 224 |
Felip E, Concha Á, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015;17:103-12. [PMID: 25351175 DOI: 10.1007/s12094-014-1248-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 225 |
Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21:166-74. [PMID: 25351743 DOI: 10.1158/1078-0432.CCR-14-1385] [Cited by in Crossref: 140] [Cited by in F6Publishing: 152] [Article Influence: 15.6] [Reference Citation Analysis]
|
| 226 |
Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis 2014;6:S502-25. [PMID: 25349702 DOI: 10.3978/j.issn.2072-1439.2014.05.19] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
|
| 227 |
Sun Q, Wu JY, Jiao SC. Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report. Oncol Lett 2014;8:2093-5. [PMID: 25295096 DOI: 10.3892/ol.2014.2468] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 228 |
Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 229 |
Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20:5686-5696. [PMID: 25228534 DOI: 10.1158/1078-0432.ccr-14-1511] [Cited by in Crossref: 213] [Cited by in F6Publishing: 235] [Article Influence: 23.7] [Reference Citation Analysis]
|
| 230 |
de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol. 2014;9:248-253. [PMID: 24419423 DOI: 10.1097/jto.0000000000000050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 231 |
Mascaux C. Aspects biologiques des cancers bronchiques. Revue des Maladies Respiratoires Actualités 2014;6:311-319. [DOI: 10.1016/s1877-1203(14)70584-1] [Reference Citation Analysis]
|
| 232 |
Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51. [PMID: 24288180 DOI: 10.1007/s40265-013-0142-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 233 |
Esfahani K, Agulnik JS, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014;4:174. [PMID: 25101240 DOI: 10.3389/fonc.2014.00174] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 234 |
Sun H, Li Y, Tian S, Wang J, Hou T. P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. PLoS Comput Biol 2014;10:e1003729. [PMID: 25033171 DOI: 10.1371/journal.pcbi.1003729] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 235 |
Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: A comprehensive review. South Asian J Cancer 2013;2:91-7. [PMID: 24455567 DOI: 10.4103/2278-330X.110506] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 236 |
Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013;5 Suppl 5:S479-S490. [PMID: 24163741 DOI: 10.3978/j.issn.2072-1439.2013.08.03] [Cited by in F6Publishing: 120] [Reference Citation Analysis]
|
| 237 |
Shackelford RE, Vora M, Mayhall K, Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 2014;5:1-14. [PMID: 24955213 DOI: 10.18632/genesandcancer.3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 238 |
Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) 2014;92:697-707. [PMID: 24852181 DOI: 10.1007/s00109-014-1165-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 239 |
Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol Rep 2014;32:33-9. [PMID: 24842630 DOI: 10.3892/or.2014.3198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 240 |
Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 637] [Cited by in F6Publishing: 666] [Article Influence: 70.8] [Reference Citation Analysis]
|
| 241 |
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662-673. [PMID: 24675041 DOI: 10.1158/2159-8290.cd-13-0846] [Cited by in Crossref: 555] [Cited by in F6Publishing: 624] [Article Influence: 61.7] [Reference Citation Analysis]
|
| 242 |
Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014;7:375-85. [PMID: 24623980 DOI: 10.2147/OTT.S38868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 243 |
Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, Ren X. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 2014;15:570-7. [PMID: 24556908 DOI: 10.4161/cbt.28162] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 244 |
Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol 2014;140:589-98. [PMID: 24509625 DOI: 10.1007/s00432-014-1589-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 245 |
Mellas N, Hijri F, Benbrahim Z, Mesbahi OE, Ismaili N. Crizotinib in non-small cell lung cancer. MC 2014;03:5-9. [DOI: 10.4236/mc.2014.31002] [Reference Citation Analysis]
|
| 246 |
Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013;12:22. [PMID: 24574860 DOI: 10.4103/1477-3163.123972] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 247 |
Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 2013;8:e82236. [PMID: 24349229 DOI: 10.1371/journal.pone.0082236] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 248 |
Neve RM, Belmont LD, Bourgon R, Evangelista M, Huang X, Schmidt M, Yauch RL, Settleman J. Discovery of Predictive Biomarkers for Anticancer Drugs. Methods and Principles in Medicinal Chemistry 2013. [DOI: 10.1002/9783527677252.ch02] [Reference Citation Analysis]
|
| 249 |
Laszlo A, Thotala D, Hallahan DE. Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J 2013;19:238-46. [PMID: 23708071 DOI: 10.1097/PPO.0b013e31829a68eb] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 250 |
Berge EM, Doebele RC. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2014;41:110-25. [PMID: 24565585 DOI: 10.1053/j.seminoncol.2013.12.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 251 |
Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther 2014;13:475-82. [PMID: 24296828 DOI: 10.1158/1535-7163.MCT-13-0817] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 252 |
Yang SH. Molecular basis of drug resistance: epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors. Tuberc Respir Dis (Seoul) 2013;75:188-98. [PMID: 24348666 DOI: 10.4046/trd.2013.75.5.188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 253 |
Villaruz LC, Burns TF, Ramfidis VS, Socinski MA. Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013;34:822-36. [PMID: 24258572 DOI: 10.1055/s-0033-1358552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 254 |
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72. [PMID: 24162815 DOI: 10.1038/nm.3352] [Cited by in Crossref: 415] [Cited by in F6Publishing: 450] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 255 |
Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 2014;83:37-43. [PMID: 24199682 DOI: 10.1016/j.lungcan.2013.09.019] [Cited by in Crossref: 57] [Cited by in F6Publishing: 65] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 256 |
Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-96. [PMID: 24101047 DOI: 10.1200/JCO.2012.45.2029] [Cited by in Crossref: 227] [Cited by in F6Publishing: 253] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 257 |
Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013;13:685-700. [PMID: 24060861 DOI: 10.1038/nrc3580] [Cited by in Crossref: 423] [Cited by in F6Publishing: 440] [Article Influence: 42.3] [Reference Citation Analysis]
|
| 258 |
Sridhar S, Al-Moallem B, Kamal H, Terrile M, Stallings RL. New insights into the genetics of neuroblastoma. Mol Diagn Ther 2013;17:63-9. [PMID: 23329364 DOI: 10.1007/s40291-013-0019-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 259 |
Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013;6:re6. [PMID: 24065147 DOI: 10.1126/scisignal.2004652] [Cited by in Crossref: 175] [Cited by in F6Publishing: 190] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 260 |
Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 2013;7:1093-102. [PMID: 23993685 DOI: 10.1016/j.molonc.2013.08.001] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 261 |
Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, Liu HP, Chu Y, Chiu YT, Wu TH, Chou LH, Chen YR, Huang SF. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013;8:e70839. [PMID: 23951022 DOI: 10.1371/journal.pone.0070839] [Cited by in Crossref: 63] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 262 |
Barlesi F, Tomasini P, Fina F, Secq V, Greillier L, Nanni-Metellus I, Garcia S, Ouafik L. [Regional molecular genetics centers in thoracic oncology: what and who should be tested?]. Bull Cancer 2013;100:737-41. [PMID: 23823903 DOI: 10.1684/bdc.2013.1774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 263 |
Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532-40. [PMID: 23833300 DOI: 10.1158/1078-0432.CCR-13-0657] [Cited by in Crossref: 233] [Cited by in F6Publishing: 261] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 264 |
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-59. [PMID: 23552377 DOI: 10.1097/JTO.0b013e318290868f] [Cited by in Crossref: 605] [Cited by in F6Publishing: 652] [Article Influence: 60.5] [Reference Citation Analysis]
|
| 265 |
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60. [PMID: 23551194 DOI: 10.5858/arpa.2012-0720-OA] [Cited by in Crossref: 329] [Cited by in F6Publishing: 367] [Article Influence: 32.9] [Reference Citation Analysis]
|
| 266 |
Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-81. [PMID: 23729361 DOI: 10.1158/1078-0432.CCR-13-0318] [Cited by in Crossref: 382] [Cited by in F6Publishing: 434] [Article Influence: 38.2] [Reference Citation Analysis]
|
| 267 |
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer 2013;13:262. [PMID: 23714228 DOI: 10.1186/1471-2407-13-262] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 268 |
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-1814. [PMID: 23154552 DOI: 10.1097/jto.0b013e3182745948] [Cited by in Crossref: 427] [Cited by in F6Publishing: 415] [Article Influence: 42.7] [Reference Citation Analysis]
|
| 269 |
West H, Oxnard GR, Doebele RC. Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 270 |
Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics 2013;7:91-101. [PMID: 23671386 DOI: 10.2147/BTT.S29026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 271 |
Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis 2013;2:e43. [PMID: 23567620 DOI: 10.1038/oncsis.2013.7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 272 |
Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068-77. [PMID: 23553849 DOI: 10.1158/1078-0432.CCR-12-3381] [Cited by in Crossref: 171] [Cited by in F6Publishing: 194] [Article Influence: 17.1] [Reference Citation Analysis]
|
| 273 |
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013;3:430-43. [PMID: 23533265 DOI: 10.1158/2159-8290.CD-12-0440] [Cited by in Crossref: 158] [Cited by in F6Publishing: 177] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 274 |
Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105-1111. [PMID: 23401436 DOI: 10.1200/jco.2012.44.5353] [Cited by in Crossref: 295] [Cited by in F6Publishing: 334] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 275 |
Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol 2013;8:3-14. [PMID: 23371030 DOI: 10.1007/s11523-013-0263-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 276 |
Wu D, Yu H, Li J. [Mechanisms of resistance to EML4-ALK inhibitors in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2013;16:48-53. [PMID: 23327874 DOI: 10.3779/j.issn.1009-3419.2013.01.09] [Reference Citation Analysis]
|
| 277 |
Broggini M, Garassino MC, Damia G. Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Manag Res 2013;5:15-20. [PMID: 23378782 DOI: 10.2147/CMAR.S29995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 278 |
Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 2013;8:e52093. [PMID: 23341890 DOI: 10.1371/journal.pone.0052093] [Cited by in Crossref: 66] [Cited by in F6Publishing: 87] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 279 |
Kwak EL, Clark JW, Shaw AT. Targeted inhibition in tumors with ALK dependency. Lung Cancer (Auckl) 2013;4:1-8. [PMID: 28210129 DOI: 10.2147/LCTT.S16313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 280 |
Craddock KJ, Tam S, Zhu C, Tsao M. Genomic Pathology of Lung Cancer. Cancer Genomics 2013. [DOI: 10.1007/978-94-007-5842-1_1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 281 |
Berghmans T, Remmelink M, Awada A. Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. Lung Cancer (Auckl) 2012;3:91-9. [PMID: 28210128 DOI: 10.2147/LCTT.S12959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 282 |
Yang L, Wu Y. Gene fusions in non-small-cell lung cancer. Lung Cancer Management 2012;1:283-92. [DOI: 10.2217/lmt.12.41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 283 |
Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Cancer Discov 2011;1:560-1. [PMID: 22211192 DOI: 10.1158/2159-8290.CD-11-0295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 284 |
Kwak EL. HGFR/MET and ALK inhibitors. Targeted Therapies for Non-Small-Cell Lung Cancer 2012. [DOI: 10.2217/ebo.12.67] [Reference Citation Analysis]
|
| 285 |
Rose-James A, Sreelekha TT. Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer Inter. 2012;2012:ID 729532. [PMID: 26316937 DOI: 10.1155/2012/729532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 286 |
Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351-75. [PMID: 22989574 DOI: 10.1634/theoncologist.2012-0311] [Cited by in Crossref: 163] [Cited by in F6Publishing: 182] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 287 |
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011-1019. [PMID: 22954507 DOI: 10.1016/s1470-2045(12)70344-3] [Cited by in Crossref: 923] [Cited by in F6Publishing: 862] [Article Influence: 83.9] [Reference Citation Analysis]
|
| 288 |
Johnson JL, Pillai S, Chellappan SP. Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int 2012;2012:940405. [PMID: 22928112 DOI: 10.1155/2012/940405] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 289 |
Mologni L, Gambacorti-passerini C. New developments in the treatment of ALK-driven malignancies. Clinical Investigation 2012;2:835-852. [DOI: 10.4155/cli.12.67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 290 |
Ebi H, Mitsudomi T. Oncogenic driver mutations. Lung Cancer Therapy Annual 7 2012. [DOI: 10.3109/9781841848679.005] [Reference Citation Analysis]
|
| 291 |
Okamoto I, Nakagawa K. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects. Cancer Sci 2012;103:1391-6. [PMID: 22568572 DOI: 10.1111/j.1349-7006.2012.02327.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 292 |
Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 2012;103:1189-94. [PMID: 22435662 DOI: 10.1111/j.1349-7006.2012.02279.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 293 |
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338-350. [PMID: 22508028 DOI: 10.1038/nrclinonc.2012.61] [Cited by in Crossref: 881] [Cited by in F6Publishing: 923] [Article Influence: 80.1] [Reference Citation Analysis]
|
| 294 |
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med 2012;2:35-49. [PMID: 25562798 DOI: 10.3390/jpm2020035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 295 |
Camidge DR, Doebele RC. Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol. 2012;9:268-277. [PMID: 22473102 DOI: 10.1038/nrclinonc.2012.43] [Cited by in Crossref: 178] [Cited by in F6Publishing: 198] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 296 |
Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 297 |
Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155-76. [PMID: 22440008 DOI: 10.1016/j.molonc.2012.02.004] [Cited by in Crossref: 367] [Cited by in F6Publishing: 382] [Article Influence: 33.4] [Reference Citation Analysis]
|
| 298 |
Thomas A, Rajan A, Giaccone G. Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am 2012;26:589-605, viii. [PMID: 22520981 DOI: 10.1016/j.hoc.2012.02.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 299 |
Maus MK, Stephens C, Zeger G, Grimminger PP, Huang E. Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method. Int J Biomed Sci 2012;8:1-6. [PMID: 23675251] [Reference Citation Analysis]
|
| 300 |
Ardini E, Galvani A. ALK Inhibitors, a Pharmaceutical Perspective. Front Oncol 2012;2:17. [PMID: 22655263 DOI: 10.3389/fonc.2012.00017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 301 |
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012;4:120ra17. [PMID: 22277784 DOI: 10.1126/scitranslmed.3003316] [Cited by in Crossref: 856] [Cited by in F6Publishing: 1022] [Article Influence: 77.8] [Reference Citation Analysis]
|
| 302 |
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472-1482. [PMID: 22235099 DOI: 10.1158/1078-0432.ccr-11-2906] [Cited by in Crossref: 787] [Cited by in F6Publishing: 899] [Article Influence: 71.5] [Reference Citation Analysis]
|
| 303 |
Płużański A, Piórek A, Krzakowski M. Crizotinib in the treatment of non-small-cell lung carcinoma. Contemp Oncol (Pozn) 2012;16:480-4. [PMID: 23788933 DOI: 10.5114/wo.2012.32477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 304 |
Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-485. [PMID: 22162641 DOI: 10.2147/dddt.s19045] [Cited by in Crossref: 111] [Cited by in F6Publishing: 132] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 305 |
Sasaki T, Jänne PA. New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011;17:7213-8. [PMID: 22010214 DOI: 10.1158/1078-0432.CCR-11-1404] [Cited by in Crossref: 58] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 306 |
Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol 2011;2:59. [PMID: 22007174 DOI: 10.3389/fphar.2011.00059] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
